Bone MarrowAntineoplastic Combined Chemotherapy ProtocolsBone Marrow CellsBone Marrow TransplantationChemotherapy, AdjuvantKidney TransplantationTreatment OutcomeCombined Modality TherapyTransplantation, HomologousCyclophosphamideAntineoplastic AgentsTransplantsCisplatinGraft RejectionDoxorubicinGraft SurvivalBone Marrow DiseasesSurvival AnalysisTransplantation, AutologousImmunosuppressive AgentsHematopoietic Stem Cell TransplantationTime FactorsDisease-Free SurvivalBone Marrow ExaminationSurvival RateHematopoietic Stem CellsPrognosisTissue DonorsBone Marrow NeoplasmsEtoposideNeoadjuvant TherapyHeart TransplantationBreast NeoplasmsNeoplasm StagingDrug Administration ScheduleTransplantationMethotrexateFollow-Up StudiesBone Marrow PurgingGraft vs Host DiseaseLung NeoplasmsLung TransplantationHematopoiesisRecurrenceWhole-Body IrradiationLeukemiaCarboplatinNeoplasmsGranulocyte Colony-Stimulating FactorNeoplasm Recurrence, LocalPaclitaxelColony-Forming Units AssayImmunosuppressionLymphoma, Non-HodgkinCyclosporineLeukemia, Myeloid, AcuteCytarabineProspective StudiesVinblastineInduction ChemotherapyHistocompatibility TestingMice, Inbred C57BLTissue and Organ ProcurementDrug Resistance, NeoplasmTaxoidsSalvage TherapyIfosfamidePrecursor Cell Lymphoblastic Leukemia-LymphomaBleomycinNeutropeniaHodgkin DiseasePostoperative ComplicationsAnemia, AplasticTransplantation ConditioningAntimetabolites, AntineoplasticAntineoplastic Agents, AlkylatingRetrospective StudiesTacrolimusAntibodies, MonoclonalLiving DonorsDeoxycytidineMultiple MyelomaOrganoplatinum CompoundsMelphalanFlow CytometryKaplan-Meier EstimateCytomegalovirus InfectionsNeoplasm MetastasisRisk FactorsCarmustineCell DifferentiationAntigens, CD34LymphomaImmunocompromised HostAcute DiseaseAnthracyclinesLeukemia, MyeloidWaiting ListsDose-Response Relationship, DrugFatal Outcome